Goodwin advised Rubius Therapeutics on the closing of its initial public offering of 12,055,450 shares of common stock at a public offering price of $23.00 per…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
